| Literature DB >> 23467510 |
Pascal Frei1, Luc Biedermann, Ole Haagen Nielsen, Gerhard Rogler.
Abstract
The use of thiopurines as immunosuppression for the treatment of refractory or chronic active inflammatory bowel disease is established for both Crohn's disease and ulcerative colitis. Nevertheless, many questions remain concerning the optimal treatment regimens of azathioprine, 6-mercaptopurine and thioguanine. We will briefly summarize dose recommendations, indications for thiopurine therapy and side effects which are relevant in clinical practice. We discuss some currently debated topics, including the combination of azathioprine and allopurinol, switching of thiopurine therapy in case of side effects, the use of azathioprine in pregnancy, the infection risk using thiopurines and the evidence when to stop thiopurines. Excellent reviews have been published on the thiopurine metabolic pathway which will not be discussed here in detail.Entities:
Keywords: Crohn’s disease; Immunosuppression; Infection; Inflammatory bowel disease; Thiopurines; Ulcerative colitis
Mesh:
Substances:
Year: 2013 PMID: 23467510 PMCID: PMC3581991 DOI: 10.3748/wjg.v19.i7.1040
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742